All‐cause mortality · participants with haematological malignancies
BMT showed no clear difference in mortality compared with PBSCT (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · participants with haematological malignancies
BMT showed no clear difference in progress, relapse or death compared with PBSCT (moderate certainty).
1 finding from 1 review
Non relapse or transplant related mortality · participants with haematological malignancies
BMT showed no clear difference in non relapse or transplant related mortality compared with PBSCT (high certainty).
1 finding from 1 review
Chronic GVHD (extensive) · participants with haematological malignancies
BMT probably leads to lower extensive chronic GvHD compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GvHD III to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD III to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Chronic GvHD overall · participants with haematological malignancies
BMT probably leads to lower chronic GvHD overall compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GVHD II to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD II to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Quality of life not reported · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion with one dose schedule showed no clear difference in bleeding Number of participants with a significant bleeding event ‐… compared with prophylactic platelet transfusions with another dose schedule (high certainty).
2 findings from 1 review
Bleeding Number of days with significant bleeding ‐ Low dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days with significant bleeding ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
2 findings from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes number of participants with a significant bleeding event compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes mortality: secondary to bleeding compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review